One-Time infusion aims to fight tough blood cancers from within
NCT ID NCT06539338
Summary
This is a first-in-human study to test the safety of a new, one-time gene therapy called INT2104 for adults with B-cell blood cancers that have returned or not responded to prior treatments. The therapy is designed to instruct the body's own immune cells to find and fight cancer cells. The main goal is to find a safe dose and understand the side effects in about 34 participants over a 5-year period.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Hospital MD Anderson
RECRUITINGMadrid, 28033, Spain
-
Peter MacCallum Cancer Centre
RECRUITINGMelbourne, Victoria, 3000, Australia
-
Westmead Hospital
RECRUITINGWestmead, New South Wales, 2145, Australia
Conditions
Explore the condition pages connected to this study.